Alnylam Centogene, Alnylam Pharmaceuticals Partner on Biomarker Study of Transthyretin Amyloidosis The study, called TRAMmoniTTR, will longitudinally monitor the clinical status of both symptomatic and asymptomatic participants with variants in the TTR gene. Alnylam, 23andMe Partner on Free Family Testing Program for Hereditary ATTR Amyloidosis 23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits. Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria Through the Alnylam Act program, patients suspected of having the rare disease or with a family history of the illness will receive testing at no cost. Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples By the end of 2019, Regeneron plans sequence the exomes of all 500,000 participants in the UK Biobank. Alnylam Expands Genetic Testing Program The company will now offer free genetic testing to patients at risk for acute hepatic porphyrias, a class of diseases for which it is developing a treatment. Apr 3, 2017 Invitae, Alnylam to Provide Free Genetic Testing for Rare Amyloidosis Condition Sep 29, 2015 Court Rules Against University of Utah in RNAi IP Inventor Dispute Feb 13, 2015 Alnylam Aims to Release Multi-program Clinical Data in 1H 2015 Premium Feb 2, 2015 Alnylam Starts Phase I/II Trial of Complement-mediated Disease Therapy Premium Jan 20, 2015 Alnylam Looks to Sell $450M in Common Stock Premium Jan 9, 2015 Alnylam, Isis Ink IP Licensing Deal Premium Dec 15, 2014 Alnylam Takes Aim at NASH, Diabetes as Part of a Return to Big Indications Premium Dec 12, 2014 Alnylam Begins Clinical Trials of ATTR, Hypercholesterolemia Drugs Premium Dec 10, 2014 Alnylam Releases Preliminary Phase I Data on Hemophilia Drug Premium Dec 10, 2014 Alnylam Files to Begin Human Trial of Complement-mediated Disease Drug Premium Dec 3, 2014 Alnylam Publishes Paper on Development of GalNAc Conjugate Delivery Technology Premium Nov 18, 2014 Dicerna to Use Tekmira LNPs for PH1 Rx amid Shift to Conjugates, New RNAi Triggers Premium Nov 17, 2014 Alnylam Releases Phase II Data on ATTR Drug, Views Adverse Events as Non-issue Premium Nov 11, 2014 Alnylam Adds Infectious Liver Disease Programs to Pipeline Premium Nov 6, 2014 Alnylam Aims Broadly with Hemophilia Drug, Advances HBV Program toward Clinic Premium Nov 6, 2014 IP Update: Recent Patents Awarded to Alnylam Pharmaceuticals, Marina Biotech, and More Premium Nov 6, 2014 Wall Street in October Proves Tumultuous for Four RNAi/microRNA Shops Premium Nov 6, 2014 Alnylam Completes Enrollment in Phase II Trial of ATTR Drug Premium Oct 30, 2014 Alnylam Files to Begin Phase I Trial of Hypercholesterolemia Drug Premium Oct 23, 2014 IP Update: Recent Patents Awarded to Devgen, Alnylam, Alcon, and More Premium Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.